PDS Biotechnology Corp
PDSB1.050USD
-0.100-8.70%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
48.97MMarket Cap
LossP/E TTM
More Details of PDS Biotechnology Corp Company
PDS Biotechnology Corporation is a clinical-stage immunotherapy company. The Company is developing a pipeline of targeted cancer immunotherapies based on its Versamune T cell-activator and Versamune in combination with its interleukin 12 (IL-12) fused antibody drug conjugate (ADC), PDS01ADC, a tumor targeting immunocytokine. PDS0101 is its lead Versamune based immunotherapy. PDS0101 combines Versamune with a mixture of short proteins (peptides) derived from the cancer-causing HPV16 viral protein. Versamune is a proprietary lipid nanoparticle and T cell activating platform. PDS0301 is an investigational tumor-targeting antibody conjugate of Interleukin 12 (IL-12) that enhances the proliferation, potency, infiltration, and longevity of T cells in the tumor microenvironment. Its Versamune immunotherapies and Versamune in combination with PDS01ADC, are utilized for treatments in oncology, and Infectimune is utilized for preventive vaccines against infectious agents.
Company Info
Ticker SymbolPDSB
Company namePDS Biotechnology Corp
IPO dateOct 01, 2015
CEODr. Frank Bedu-Addo, Ph.D.
Number of employees24
Security typeOrdinary Share
Fiscal year-endOct 01
Address303A College Road East
CityPRINCETON
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code08540
Phone18002083343
Websitehttps://www.pdsbiotech.com
Ticker SymbolPDSB
IPO dateOct 01, 2015
CEODr. Frank Bedu-Addo, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Frank Bedu-Addo, Ph.D.
Dr. Frank Bedu-Addo, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
690.87K
--
Mr. Stephen C. (Steve) Glover
Mr. Stephen C. (Steve) Glover
Independent Chairman of the Board
Independent Chairman of the Board
78.85K
--
Mr. Gregory Gene (Greg) Freitag, CPA., J.D.
Mr. Gregory Gene (Greg) Freitag, CPA., J.D.
Independent Director
Independent Director
61.21K
--
Ms. Kamil Ali-Jackson, Esq., J.D.
Ms. Kamil Ali-Jackson, Esq., J.D.
Independent Director
Independent Director
11.76K
--
Dr. Ilian Petkov Iliev
Dr. Ilian Petkov Iliev
Director
Director
--
--
Mr. Mike Moyer
Mr. Mike Moyer
IR Contact Officer
IR Contact Officer
--
--
Mr. Spencer Brown
Mr. Spencer Brown
Senior Vice President, Compliance Officer, General Counsel, Corporate Secretary
Senior Vice President, Compliance Officer, General Counsel, Corporate Secretary
--
--
Mr. Stephan Toutain
Mr. Stephan Toutain
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Kirk V. Shepard, M.D.
Dr. Kirk V. Shepard, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Otis W. Brawley, M.D.
Dr. Otis W. Brawley, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Frank Bedu-Addo, Ph.D.
Dr. Frank Bedu-Addo, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
690.87K
--
Mr. Stephen C. (Steve) Glover
Mr. Stephen C. (Steve) Glover
Independent Chairman of the Board
Independent Chairman of the Board
78.85K
--
Mr. Gregory Gene (Greg) Freitag, CPA., J.D.
Mr. Gregory Gene (Greg) Freitag, CPA., J.D.
Independent Director
Independent Director
61.21K
--
Ms. Kamil Ali-Jackson, Esq., J.D.
Ms. Kamil Ali-Jackson, Esq., J.D.
Independent Director
Independent Director
11.76K
--
Dr. Ilian Petkov Iliev
Dr. Ilian Petkov Iliev
Director
Director
--
--
Mr. Mike Moyer
Mr. Mike Moyer
IR Contact Officer
IR Contact Officer
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Aug 16
Updated: Sat, Aug 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Armistice Capital LLC
4.79%
The Vanguard Group, Inc.
4.18%
Bedu-Addo (Frank)
1.48%
BlackRock Institutional Trust Company, N.A.
1.08%
Sykes (Richard)
0.95%
Other
87.50%
Shareholders
Shareholders
Proportion
Armistice Capital LLC
4.79%
The Vanguard Group, Inc.
4.18%
Bedu-Addo (Frank)
1.48%
BlackRock Institutional Trust Company, N.A.
1.08%
Sykes (Richard)
0.95%
Other
87.50%
Shareholder Types
Shareholders
Proportion
Investment Advisor
7.09%
Hedge Fund
5.81%
Individual Investor
3.03%
Investment Advisor/Hedge Fund
1.91%
Research Firm
0.83%
Bank and Trust
0.25%
Other
81.08%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
188
9.63M
21.07%
+1.19M
2025Q1
201
9.77M
22.08%
+1.54M
2024Q4
205
5.67M
12.73%
-3.40M
2024Q3
205
5.76M
15.58%
-3.85M
2024Q2
208
6.94M
18.83%
-4.50M
2024Q1
195
8.96M
25.12%
-3.13M
2023Q4
194
9.68M
31.15%
-1.91M
2023Q3
192
9.20M
29.70%
-3.29M
2023Q2
183
9.26M
30.03%
-1.73M
2023Q1
149
11.76M
39.00%
-275.25K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Armistice Capital LLC
4.42M
9.67%
+4.42M
--
Mar 31, 2025
The Vanguard Group, Inc.
1.51M
3.3%
+4.41K
+0.29%
Mar 31, 2025
Bedu-Addo (Frank)
690.87K
1.51%
--
--
Apr 17, 2025
BlackRock Institutional Trust Company, N.A.
480.97K
1.05%
-4.48K
-0.92%
Mar 31, 2025
Sykes (Richard)
445.11K
0.97%
--
--
Apr 17, 2025
UBS Financial Services, Inc.
245.33K
0.54%
+221.67K
+936.97%
Mar 31, 2025
Geode Capital Management, L.L.C.
437.88K
0.96%
+20.66K
+4.95%
Mar 31, 2025
William Blair & Company, L.L.C. (Research)
257.20K
0.56%
+99.70K
+63.30%
Mar 31, 2025
State Street Global Advisors (US)
133.33K
0.29%
--
--
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
